Table 1. Summary of differences in developmental milestone findings for each ART regimen compared to control.
| Days delay vs. control | ATV/r/ABC/3TC | ATV/r/TDF/FTC | ||
|---|---|---|---|---|
| Male | Female | Male | Female | |
| Negative geotaxis | 2 days delay | 2.5 days delay | 2 days delay | 2.5 days delay |
| Cliff aversion | 2 days delay | 2 days delay | 2 days delay | 2 days delay |
| Rooting | 1 day delay | No delay | 1 day delay | No delay |
| Outer ear opening | No delay | 0.5 day delay | 0.5 day delay | 0.5 day delay |
| Ear twitch | No delay | 1 day delay | 1.5 days delay | 1.5 days delay |
| Forelimb grasp | No delay | 1 day delay | No delay | No delay |
| Surface righting | No delay | No delay | No delay | No delay |
| Air righting | No delay | No delay | No delay | No delay |
| Auditory reflex | No delay | No delay | No delay | No delay |
| Open field traversal | No delay | No delay | No delay | No delay |
| Eyes opening | No delay | No delay | No delay | No delay |
| Incisors eruption | No delay | No delay | No delay | No delay |
| Fur appearance | No delay | No delay | No delay | No delay |
| Olfaction | Deficit present | No deficit | No deficit | No deficit |
ATV/r, ritonavir-boosted atazanavir; ABC, abacavir; 3TC, lamivudine; TDF, tenofovir; FTC, emtricitabine.